Journal: Cell Reports Medicine
Article Title: Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
doi: 10.1016/j.xcrm.2020.100163
Figure Lengend Snippet: MGD019 Molecular Structure and Bispecific Binding to PD-1 and CTLA-4 (A) MGD019 is a tetravalent bispecific (2 × 2) Fc-bearing DART molecule. (B) Binding of MGD019 (red diamonds), parental PD-1 mAb retifanlimab (blue squares), parental CTLA-4 mAb 4B6 (green triangles), or isotype control (black circles) to Jurkat/PD-1 cells and blockade of PD-L1 binding to the cells. (C) Binding to Jurkat/CTLA-4 cells and blockade of B7-1 binding to the cells. (D) Re-activation of β-galactosidase (β-gal) upon co-engagement of PD-1 and CTLA-4 by MGD019 in PathHunter PD-1 + CTLA-4 + assay. Error bars depict standard errors of the mean (SEMs). (E) Binding to in vitro -stimulated, PD-1 + /CTLA-4 + primary T cells and blockade of B7.1 binding to Jurkat PD-1 + /CTLA-4 + cells. (F) Blockade B7.1 binding to Jurkat PD-1 + /CTLA-4 + by MGD019 or CTLA-4 mAbs alone or in the presence of a 10× concentration of competing PD-1 mAbs (open red diamonds and purple crosses, respectively). (G) Interaction of MGD019 with single- and dual-expressing cells. Average (EC 50 ) values of PD-1 (blue) and CTLA-4 (yellow) ligand binding blockade . Representative experiments out of ≥3 independent repeats are shown in (B)–(F). See also and and .
Article Snippet: Human B7-1 protein (biotinylated) , BPS Bioscience , Cat# 71114.
Techniques: Binding Assay, Activation Assay, In Vitro, Concentration Assay, Expressing, Ligand Binding Assay